Antitumor activity of Noscapine in combination with doxorubicin in triple negative breast cancer

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Chougule, Mahavir B ^a   Patel, Apurva R ^b   Jackson, Tanise ^b   Singh, Mandip ^b  

^a UNIVERSITY OF HAWAII AT HILO   (United States)

^b FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD31 ANTIGEN; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NOSCAPINE; VASCULOTROPIN; ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; MONOTHERAPY; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; CELL PROLIFERATION; DNA FRAGMENTATION; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE; VASCULARIZATION;

MUS;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA FRAGMENTATION; DOXORUBICIN; DRUG SYNERGISM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; NOSCAPINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79952637468     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017733     Document Type: Article

References (45)

1. Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, et al. (2009) Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 9: 29-33.
2. Irvin WJ Jr, Carey LA, (2008) What is triple-negative breast cancer? Eur J Cancer 44: 2799-2805.
3. Stockmans G, Deraedt K, Wildiers H, Moerman P, Paridaens R, (2008) Triple-negative breast cancer. Curr Opin Oncol 20: 614-620.
4. Moulder S, Hortobagyi GN, (2008) Advances in the treatment of breast cancer. Clin Pharmacol Ther 83: 26-36.
5. Buzdar AU, (2003) Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist 8: 335-341.
6. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, et al. (2007) Prognostic markers in triple-negative breast cancer. Cancer 109: 25-32.
7. Aneja R, Zhou J, Zhou B, Chandra R, Joshi HC, (2006) Treatment of hormone-refractory breast cancer: apoptosis and regression of human tumors implanted in mice. Mol Cancer Ther 5: 2366-2377.
8. Perez EA, (2009) Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 8: 2086-2095.
9. van Zuylen L, Verweij J, Sparreboom A, (2001) Role of formulation vehicles in taxane pharmacology. Invest New Drugs 19: 125-141.
10. Markman M, (2003) Managing taxane toxicities. Support Care Cancer 11: 144-147.
11. Anderson JT, Ting AE, Boozer S, Brunden KR, Crumrine C, et al. (2005) Identification of novel and improved antimitotic agents derived from noscapine. J Med Chem 48: 7096-7098.
12. Anderson JT, Ting AE, Boozer S, Brunden KR, Danzig J, et al. (2005) Discovery of S-phase arresting agents derived from noscapine. J Med Chem 48: 2756-2758.
13. Landen JW, Lang R, McMahon SJ, Rusan NM, Yvon AM, et al. (2002) Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res 62: 4109-4114.
14. Zhou J, Gupta K, Yao J, Ye K, Panda D, et al. (2002) Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine. J Biol Chem 277: 39777-39785.
15. Aneja R, Zhou J, Vangapandu SN, Zhou B, Chandra R, et al. (2006) Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule agent, EM011. Blood 107: 2486-2492.
16. Heidari N, Goliaei B, Moghaddam PR, Rahbar-Roshandel N, Mahmoudian M, (2007) Apoptotic pathway induced by noscapine in human myelogenous leukemic cells. Anticancer Drugs 18: 1139-1147.
17. Landen JW, Hau V, Wang M, Davis T, Ciliax B, et al. (2004) Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin Cancer Res 10: 5187-5201.
18. Jackson T, Chougule MB, Ichite N, Patlolla RR, Singh M, (2008) Antitumor activity of noscapine in human non-small cell lung cancer xenograft model. Cancer Chemother Pharmacol 63: 117-126.
19. Ye K, Ke Y, Keshava N, Shanks J, Kapp JA, et al. (1998) Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc Natl Acad Sci U S A 95: 1601-1606.
20. Aneja R, Lopus M, Zhou J, Vangapandu SN, Ghaleb A, et al. (2006) Rational design of the microtubule-targeting anti-breast cancer drug EM015. Cancer Res 66: 3782-3791.
21. Yamamoto Y, Iwase H, (2010) Clinicopathological features and treatment strategy for triple-negative breast cancer. Int J Clin Oncol.
22. Keam B, Im SA, Kim HJ, Oh DY, Kim JH, et al. (2007) Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer 7: 203.
23. Hardenbergh PH, Recht A, Gollamudi S, Come SE, Hayes DF, et al. (1999) Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer. Int J Radiat Oncol Biol Phys 45: 69-72.
24. Patlolla RR, Chougule M, Patel AR, Jackson T, Tata PN, et al. (2010) Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release 144: 233-241.
25. Ichite N, Chougule MB, Jackson T, Fulzele SV, Safe S, et al. (2009) Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer. Clin Cancer Res 15: 543-552.
26. Zhao L, Wientjes MG, Au JL, (2004) Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 10: 7994-8004.
27. Chougule M, Patel AR, Sachdeva P, Jackson T, Singh M, (2010) Anticancer activity of Noscapine, an opioid alkaloid in combination with Cisplatin in human non-small cell lung cancer. Lung Cancer.
28. Hiser L, Herrington B, Lobert S, (2008) Effect of noscapine and vincristine combination on demyelination and cell proliferation in vitro. Leuk Lymphoma 49: 1603-1609.
29. Wang SJ, Gao Y, Chen H, Kong R, Jiang HC, et al. (2010) Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Lett 293: 99-108.
30. Newcomb EW, Lukyanov Y, Alonso-Basanta M, Esencay M, Smirnova I, et al. (2008) Antiangiogenic effects of noscapine enhance radioresponse for GL261 tumors. Int J Radiat Oncol Biol Phys 71: 1477-1484.
31. Aneja R, Dhiman N, Idnani J, Awasthi A, Arora SK, et al. (2007) Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent. Cancer Chemother Pharmacol 60: 831-839.
32. Dahlstrom B, Mellstrand T, Lofdahl CG, Johansson M, (1982) Pharmacokinetic properties of noscapine. Eur J Clin Pharmacol 22: 535-539.
33. Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE, et al. (2008) Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 100: 1167-1178.
34. Ewens A, Luo L, Berleth E, Alderfer J, Wollman R, et al. (2006) Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice. Cancer Res 66: 5419-5426.
35. Bandyopadhyay A, Wang L, Agyin J, Tang Y, Lin S, et al. (2010) Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS One 5: e10365.
36. Pan Q, Bao LW, Kleer CG, Brewer GJ, Merajver SD, (2003) Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma. Mol Cancer Ther 2: 617-622.
37. Zamorano J, Mora AL, Boothby M, Keegan AD, (2001) NF-kappa B activation plays an important role in the IL-4-induced protection from apoptosis. Int Immunol 13: 1479-1487.
38. Sung B, Ahn KS, Aggarwal BB, (2010) Noscapine, a benzylisoquinoline alkaloid, sensitizes leukemic cells to chemotherapeutic agents and cytokines by modulating the NF-kappaB signaling pathway. Cancer Res 70: 3259-3268.
39. Liu M, Luo XJ, Liao F, Lei XF, Dong WG, (2010) Noscapine induces mitochondria-mediated apoptosis in gastric cancer cells in vitro and in vivo. Cancer Chemother Pharmacol.
40. Barken I, Geller J, Rogosnitzky M, (2008) Noscapine inhibits human prostate cancer progression and metastasis in a mouse model. Anticancer Res 28: 3701-3704.
41. Mahmoudian M, Rahimi-Moghaddam P, (2009) The anti-cancer activity of noscapine: a review. Recent Pat Anticancer Drug Discov 4: 92-97.
42. Aneja R, Ghaleb AM, Zhou J, Yang VW, Joshi HC, (2007) p53 and p21 determine the sensitivity of noscapine-induced apoptosis in colon cancer cells. Cancer Res 67: 3862-3870.
43. Menendez JA, del Mar Barbacid M, Montero S, Sevilla E, Escrich E, et al. (2001) Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells. Eur J Cancer 37: 402-413.
44. Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, et al. (2001) Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 91: 2026-2032.
45. Karna P, Sharp SM, Yates C, Prakash S, Aneja R, (2009) EM011 activates a survivin-dependent apoptotic program in human non-small cell lung cancer cells. Mol Cancer 8: 93.